Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMPIRIKAL – A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL)

Trial Profile

EMPIRIKAL – A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirococept (Primary)
  • Indications Reperfusion injury
  • Focus Therapeutic Use
  • Acronyms EMPIRIKAL
  • Most Recent Events

    • 06 Jun 2017 Trial design published in the Trials.
    • 11 Mar 2016 Accrual to Date is 3% as per United Kingdom Clinical Research Network record.
    • 11 Mar 2016 Planned End Date changed from 30 Apr 2016 to 31 Mar 2017 as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top